Repligen Corp
RGEN
查看详细走势图
162.760USD
-0.580-0.36%
交易中 （美东）报价延迟15分钟
9.16B总市值
5833.69市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.36%
5天
+0.46%
1月
-2.08%
6月
+33.70%
今年开始到现在
-0.67%
1年
-1.89%
查看详细走势图
TradingKey Repligen Corp股票评分
单位: USD 更新时间: 2026-01-26操作建议
Repligen Corp当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在医疗设备与耗材行业排名14/205位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价190.62。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Repligen Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Repligen Corp亮点
亮点风险
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
业绩转亏
公司业绩转亏，最新年度亏损美元
估值高估
公司最新PE估值5854.48，处于3年历史高位
机构加仓
最新机构持股62.39M股，环比增加3.41%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值96.00
分析师目标
根据
22
位分析师
买入
评级
190.624
目标均价
+17.43%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Repligen Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Repligen Corp简介
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
公司代码RGEN
公司Repligen Corp
CEOLoeillot (Olivier)
网址https://www.repligen.com/
相关品种
-15.49%
-1.07%
+0.41%
-1.51%
-1.46%
-0.25%
-0.35%
-0.44%
+6.84%
-9.05%
-7.15%
-1.36%
-0.50%
+0.70%
-0.58%
-0.36%
+0.24%
+0.11%
+0.07%
+0.33%
